Toronto-based Tm Bioscience Corporation recently announced a collaborative study involving its Tag-It™ reagent test for coagulation disorders. The company specializes in DNA testing for genetic mutations associated with cystic fibrosis, toxicology, coagulation and other disorders. The company’s tests for variations in the genes P450-2C9 and VKORC1 will be used in a comprehensive prospective clinical study of more than 1,000 patients taking the blood thinner warfarin.
Medco Health Solutions, Inc., a large pharmacy benefits manager based in Franklin Lakes, NJ, and Mayo Collaborative Services, Inc., an arm of the Mayo Clinic in Rochester, MN, will evaluate the results of the Tag-It™ reagents tests. They will assess the potential use of genetic testing to help physicians to determine optimum doses of blood thinners for individual patients.
“Each year, approximately two million people in the United States begin therapy with warfarin to prevent blood clots; however, as many as one in five will suffer adverse events from mild to severe bleeding,” said Dr. Thomas Moyer, co-primary investigator for the study and medical director for Mayo Collaborative Services, Inc. “Genetic testing can provide valuable information about the rate at which patients will metabolize the drug, helping physicians prescribe the most appropriate dose of the medication for a particular patient.”
The study will begin in the first quarter of 2007 and will be completed by the end of the year.
Source: Tm Bioscience Corporation press release dated January 30, 2007